Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer: A systematic review

International Archives of Otorhinolaryngology

Volumn 20, Issue 4, 2016, Pages 382-389

  Nguyen, Austin ^a   Bhavsar, Sheila ^a   Riley, Erinn ^a   Caponetti, Gabriel ^a   Agrawal, Devendra ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

advanced glycosylation end product specific receptor; head and neck neoplasms; HMGB1 protein

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN;

ANGIOGENESIS; CANCER SIZE; CANCER STAGING; DIAGNOSTIC VALUE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

EID: 84992133878     PISSN: 18099777     EISSN: 18094864     Source Type: Journal    
DOI: 10.1055/s-0036-1583168     Document Type: Review

References (41)

1. Czura C. J., Wang H., Tracey K. J. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res: 2001; 7 4 315 321
2. Cheng B. Q., Jia C. Q., Liu C. T., et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis: 2008; 40 6 446 452
3. Lee H., Song M., Shin N., et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS ONE: 2012; 7 4 e34318
4. Goodwin G. H., Sanders C., Johns E. W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem: 1973; 38 1 14 19
5. Pallier C., Scaffidi P., Chopineau-Proust S., et al. Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell: 2003; 14 8 3414 3426
6. Lotze M. T., Tracey K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol: 2005; 5 4 331 342
7. Zhang Z., Wang M., Zhou L., et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res: 2015; 34 1 51 60
8. Evans A., Lennard T. W., Davies B. R. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol: 2004; 88 2 86 99
9. Palumbo R., Sampaolesi M., De Marchis F., et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol: 2004; 164 3 441 449
10. Wang H., Yang H., Tracey K. J. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med: 2004; 255 3 320 331
11. Hori O., Brett J., Slattery T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem: 1995; 270 43 25752 25761
12. Nguyen A. H., Berim I. G., Agrawal D. K. Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells. Expert Rev Clin Immunol: 2015; 11 7 849 857
13. Chuah Y. K., Basir R., Talib H., Tie T. H., Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm: 2013; 2013 403460
14. Schlueter C., Weber H., Meyer B., et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol: 2005; 166 4 1259 1263
15. Srinivasan M., Banerjee S., Palmer A., et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer: 2014; 5 3 127 139
16. Diener K. R., Al-Dasooqi N., Lousberg E. L., Hayball J. D. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol: 2013; 91 7 443 450
17. Sasahira T., Sasaki T., Kuniyasu H. Interleukin-15 and transforming growth factor alpha are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res: 2005; 24 1 69 74
18. Luo Y., Chihara Y., Fujimoto K., et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer: 2013; 49 3 741 751
19. Kang R., Tang D., Schapiro N. E., et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ: 2010; 17 4 666 676
20. Taguchi A., Blood D. C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature: 2000; 405 6784 354 360
21. Campana L., Bosurgi L., Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol: 2008; 20 5 518 523
22. Ellerman J. E., Brown C. K., de Vera M., et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res: 2007; 13 10 2836 2848
23. Kang R., Zhang Q., Zeh H. J. III, Lotze M. T., Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res: 2013; 19 15 4046 4057
24. Tang D., Kang R., Zeh H. J. III, Lotze M. T. High-mobility group box 1 and cancer. Biochim Biophys Acta: 2010; 1799 1-2 131 140
25. Kuniyasu H., Chihara Y., Kondo H., Ohmori H., Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep: 2003; 10 6 1863 1868
26. Tarbé N., Evtimova V., Burtscher H., Jarsch M., Alves F., Weidle U. H. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res: 2001; 21 5 3221 3228
27. Maeda S., Hikiba Y., Shibata W., et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun: 2007; 360 2 394 400
28. Leman E. S., Madigan M. C., Brünagel G., Takaha N., Coffey D. S., Getzenberg R. H. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem: 2003; 88 3 599 608
29. Dolde C. E., Mukherjee M., Cho C., Resar L. M. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat: 2002; 71 3 181 191
30. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin: 2015; 65 1 5 29
31. Sasahira T., Kirita T., Bhawal U. K., et al. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch: 2007; 450 3 287 295
32. Landesberg R., Woo V., Huang L., et al. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod: 2008; 105 5 617 624
33. Tsuji A., Wakisaka N., Kondo S., Murono S., Furukawa M., Yoshizaki T. Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin Cancer Res: 2008; 14 17 5368 5375
34. Su S., Chien M., Lin C., Chen M., Yang S. RAGE gene polymorphism and environmental factor in the risk of oral cancer. J Dent Res: 2015; 94 3 403 411
35. Sasahira T., Kirita T., Oue N., et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci: 2008; 99 9 1806 1812
36. Wu D., Ding Y., Wang S., Zhang Q., Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol: 2008; 216 2 167 175
37. Liu Y., Xie C., Zhang X., et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer: 2010; 46 16 3007 3015
38. Wild C. A., Brandau S., Lotfi R., et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol: 2012; 48 5 409 416
39. Qiu G., Li Y., Liu Z., Wang M., Ge J., Bai X. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol: 2014; 31 12 316
40. Hanakawa H., Orita Y., Sato Y., et al. Does HMGB1 predict occult neck lymph node metastasis in early tongue carcinoma? A case-control study of 26 patients. J Laryngol Otol: 2014; 128 10 926 931
41. Supic G., Kozomara R., Zeljic K., et al. HMGB1 genetic polymorphisms in oral squamous cell carcinoma and oral lichen planus patients. Oral Dis: 2015; 21 4 536 543